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Abstract
The aetiological agents of many invasive fungal infections are saprobes and opportunistic pathogens. Some of these fungi are darkly
pigmented due to melanin production and traditionally have been named ‘dematiaceous’. The melanized fungi cause a wide array of clinical
syndromes ranging from superﬁcial to deep-seated infections. Diagnosis relies on histopathological examination of clinical specimens and on
examination of cultures. Sequencing is recommended for accurate species identiﬁcation, especially for unusual or newly described
pathogens. In cases of mycetoma and chromoblastomycosis, pathognomonic histological ﬁndings are useful and the Fontana–Masson stain,
speciﬁc for melanin, usually conﬁrms the diagnosis. There are no standardized therapies but voriconazole, posaconazole and itraconazole
demonstrate the most consistent in vitro activity against this group of fungi. Oral itraconazole has been considered the drug of choice, given
the extensive clinical experience with this drug. However, voriconazole may presumably be superior for central nervous system infections
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because of its ability to achieve good levels in the cerebrospinal ﬂuid. Posaconazole is a well-tolerated alternative drug, backed by less clinical
experience but with excellent salvage treatment results after failure of other antifungals. Amphotericin B has been useful as alternative
therapy in some cases. Combination antifungal therapy is recommended for cerebral abscesses when surgery is not possible and for
disseminated infections in immunocompromised patients.
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Introduction
A panel of experts of the European Fungal Infection Study
Group (EFISG) of the European Society of Clinical Micro-
biology and Infectious Diseases (ESCMID) undertook a data
review and compiled guidelines for the diagnosis and
management of infections caused by melanized (black) fungi.
The deep-seated infection caused by these fungi is often
referred to as phaeohyphomycosis. Many infections, how-
ever, are superﬁcial and mild, or cause cutaneous or
pulmonary colonization only. In addition, many species of
black fungi have a cosmopolitan presence and are widely
distributed in the environment and the possibility that a
suspected clinical isolate might be a contaminant must be
considered. The course of infection differs with the species,
so for clinical management it is paramount to obtain an
accurate species identiﬁcation. Although sizeable numbers of
these rare fungal pathogens have been implicated in
human infections, we have reviewed only the most common
ones.
Methods
The guideline development followed the AGREE II method
(Appraisal of guidelines for research and evaluation II; http://
www.agreetrust.org/resource-centre/agree-ii/, accessed 13
December 2013). The overall objective of the guidelines has
been on the diagnosis and management of deep-seated
phaeohyphomycosis, including disseminated infections. In
addition, superﬁcial and allergic manifestations caused by these
fungi are also brieﬂy discussed. The deﬁnition of the strength
of recommendation and the quality of the published evidence
are deﬁned in Table 1. The health questions covered by the
guidelines are speciﬁcally described in the Tables 2–4. The
population to whom the recommendations are meant to apply
is any patient suffering from phaeohyphomycosis. The expert
panel (35 members) was set up by ESCMID/EFISG and
European Confederation of Medical Mycology (ECMM) includ-
ing clinical microbiologists, infectious diseases experts, paedi-
atricians, haematologists and intensive care unit experts taking
into account the target users of these guidelines. Competing
interests of guideline development group members were
recorded and addressed. An expert subgroup (AC, MCE, JG,
SDH, SK, OAC, JFM) reviewed the available literature. The
other experts of the panel acted as external reviewers. The
members actively shared their views and documents by email,
teleconferences and face-to face meetings during 2012–2013.
TABLE 1. System for grading strength of recommendation
and quality of evidence about diagnostic procedures and
therapy of infections by black fungi
Grade of
recommendation Deﬁnition
Strength of recommendation
Grade A ESCMID (EFISG) and ECMM strongly support
a recommendation for use
Grade B ESCMID (EFISG) and ECMM moderately support
a recommendation for use
Grade C ESCMID (EFISG) and ECMM marginally support
a recommendation for use
Grade D ESCMID (EFISG) and ECMM support a
recommendation against use
Level of evidence Deﬁnition
Quality of evidence accepted
Level I Evidence from at least one properly designed randomized,
controlled trial
Level II Evidence from at least one well-designed clinical trial,
without randomization; from cohort or case–control
analytical studies (preferably from more than one centre);
from multiple time series; or from dramatic results of
uncontrolled experiments
Level III Evidence from opinions of respected authorities, based
on clinical experience, descriptive case studies, or reports
of expert committees
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 3), 47–75
48 Clinical Microbiology and Infection, Volume 20 Supplement 3, April 2014 CMI
T
A
B
L
E
2
.
D
is
e
a
se
sp
e
c
tr
u
m
o
f
a
g
e
n
ts
o
f
p
h
a
e
o
h
y
p
h
o
m
y
c
o
si
s
w
it
h
th
e
ir
in
vi
tr
o
a
n
ti
fu
n
g
a
l
su
sc
e
p
ti
b
il
it
y
p
ro
ﬁ
le
A
e
ti
o
lo
g
ic
a
l
a
g
e
n
ts
[r
e
fe
re
n
c
e
s]
M
o
st
c
o
m
m
o
n
d
e
sc
ri
b
e
d
in
fe
c
ti
o
n
s
S
p
e
c
ie
s
In
vi
tr
o
su
sc
e
p
ti
b
il
it
y
(M
IC
ra
n
g
e
,
m
g
/L
)a
A
M
B
IT
C
V
R
C
P
O
S
IS
A
F
C
F
L
U
E
C
H
IN
O
T
E
R
B
A
lte
rn
ar
ia
[3
8
,5
5
,1
6
7
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
si
n
u
si
ti
s,
k
e
ra
ti
ti
s,
A
B
P
M
,
d
is
se
m
in
at
e
d
d
is
e
as
e
A
.
al
te
rn
at
a
0
.2
5
–1
.0
0
.2
5
–1
.0
1
.0
–4
.0
0
.1
2
–0
.5
0
–
8
.0
–>
6
4
.0
8
.0
–3
2
.0
0
.5
0
–1
.0
>
1
6
.0
A
.
in
fe
ct
or
ia
0
.2
5
–1
.0
0
.2
5
–1
.0
1
.0
–4
.0
0
.0
6
–0
.1
2
–
1
6
.0
–>
6
4
.0
1
6
.0
–3
2
.0
1
.0
>
8
.0
A
lte
rn
ar
ia
sp
p
.
0
.0
3
–4
.0
1
.0
2
.0
1
.0
–
1
6
.0
–>
6
4
.0
1
6
.0
–>
6
4
.0
>
1
6
.0
1
6
.0
A
cr
op
hi
al
op
ho
ra
[1
8
3
–1
8
5
]
B
ra
in
ab
sc
e
ss
,
o
cu
la
r
an
d
lu
n
g
in
fe
ct
io
n
A
.
fu
si
sp
or
a
0
.2
5
–4
.0
0
.0
6
–0
.2
5
0
.1
2
–2
.0
0
.1
2
5
–2
.0
>
6
4
.0
8
.0
–3
2
.0
–
–
A
ur
eo
ba
si
di
um
[2
1
1
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
o
cu
la
r
in
fe
ct
io
n
,
ra
re
d
ee
p
in
fe
ct
io
n
,
fu
n
ga
em
ia
A
.
p
ul
lu
la
ns
0
.0
1
–1
6
.0
0
.0
1
–2
.0
0
.0
1
–1
6
.0
0
.0
1
–4
.0
–
–
4
.0
–6
4
.0
0
.0
6
–8
.0
–
B
ip
ol
ar
is
[2
1
3
,2
4
2
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
si
n
u
si
ti
s,
o
cu
la
r
in
fe
ct
io
n
,
p
n
e
u
m
o
n
ia
,
ce
re
b
ra
l
in
fe
ct
io
n
,
d
is
se
m
in
at
e
d
d
is
e
as
e
B
.
ha
w
ai
ie
ns
is
0
.1
2
–0
.2
5
0
.0
3
–0
.5
0
.2
5
–2
.0
0
.0
3
–0
.5
–
>
6
4
.0
2
.0
–3
2
.0
0
.5
0
–1
.0
–
B
.
au
st
ra
lie
ns
is
0
.0
6
–0
.1
2
0
.2
5
–0
.5
0
.0
5
–1
.0
0
.0
6
–
>
6
4
.0
8
.0
–1
6
.0
1
.0
–
B
.
sp
ic
ife
ra
0
.0
3
–4
.0
0
.0
3
–8
.0
0
.2
5
–4
.0
0
.0
3
–2
.0
–
>
6
4
.0
4
.0
–>
6
4
.0
0
.2
5
–2
.0
–
C
ha
et
om
iu
m
[1
4
3
,2
5
7
,2
5
8
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
p
n
e
u
m
o
n
ia
,
b
ra
in
ab
sc
e
ss
C
.
gl
ob
os
um
0
.5
0
–8
.0
0
.0
3
–0
.5
0
0
.5
0
–
–
3
2
.0
–>
6
4
.0
>
6
4
.0
–
–
C
.
p
er
lu
ci
du
m
0
.2
5
0
.0
1
–0
.0
6
0
.5
0
0
.0
6
–0
.1
2
–
–
–
8
.0
–>
1
6
.0
–
C
la
do
p
hi
al
op
ho
ra
[8
7
,1
2
3
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
b
ra
in
ab
sc
e
ss
C
.
ca
rr
io
ni
i
0
.5
–8
.0
0
.0
1
–0
.1
2
0
.0
1
–1
.0
0
.0
1
–0
.0
6
0
.0
1
–1
.0
–
4
.0
–6
4
.0
0
.2
5
–4
.0
0
.0
1
–1
.0
C
.
ba
nt
ia
na
0
.1
2
–2
.0
0
.0
1
–0
.2
5
0
.1
2
–4
.0
0
.0
1
–0
.2
5
0
.0
1
–1
.0
–
1
6
.0
–6
4
.0
1
.0
–8
.0
–
C
ur
vu
la
ri
a
[2
7
7
,2
8
4
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
si
n
u
si
ti
s,
k
e
ra
ti
ti
s,
A
B
P
M
,
p
e
ri
to
n
it
is
,
ce
re
b
ra
l
in
fe
ct
io
n
,
d
is
se
m
in
at
e
d
d
is
e
as
e
C
.
se
ne
ga
le
ns
is
0
.0
6
–0
.5
0
0
.0
6
–1
.0
0
.1
2
–4
.0
0
.0
3
–0
.5
0
–
6
4
.0
–>
6
4
.0
2
.0
–1
6
.0
0
.5
0
–2
.0
–
C
.
lu
na
ta
0
.1
2
–>
1
6
.0
0
.1
2
–>
1
6
.0
0
.2
5
–1
.0
0
.0
3
–0
.5
0
–
>
6
4
.0
2
.0
–6
4
.0
0
.5
0
–>
1
6
.0
–
C
ur
vu
la
ri
a
sp
p
.
0
.0
6
–>
1
6
.0
0
.0
3
–>
1
6
.0
0
.1
5
–>
1
6
0
.0
3
–4
.0
–
6
4
.0
–>
6
4
.0
1
.0
–>
6
4
.0
0
.5
0
–>
1
6
.0
–
E
xo
p
hi
al
a
[3
3
4
–3
3
8
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
p
n
e
u
m
o
n
ia
,
b
ra
in
ab
sc
e
ss
,
d
is
se
m
in
at
e
d
d
is
e
as
e
E
.
je
an
se
lm
ei
0
.2
5
–2
.0
0
.0
1
–0
.2
5
0
.0
6
–2
.0
0
.0
1
–0
.0
6
0
.2
5
–2
.0
–
8
.0
–3
2
.0
0
.0
6
–8
.0
–
E
.
de
rm
at
iti
di
s
0
.0
1
–0
.5
0
0
.0
3
–0
.5
0
.0
6
–1
.0
0
.0
3
–0
.2
5
0
.0
3
–1
.0
–
2
.0
–3
2
.0
0
.2
5
–8
.0
0
–
E
.
sp
in
ife
ra
0
.2
5
–4
.0
0
.0
1
–0
.1
2
0
.0
6
–1
.0
0
.0
1
–0
.0
6
2
.0
0
.1
2
–>
6
4
.0
1
6
.0
–>
6
4
.0
4
.0
0
.0
3
–2
.0
E
xs
er
oh
ilu
m
[3
4
0
,3
7
5
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
k
e
ra
ti
ti
s,
m
e
n
in
gi
ti
s
an
d
sp
in
al
in
fe
ct
io
n
,
ar
th
ri
ti
s,
d
is
se
m
in
at
e
d
d
is
e
as
e
E
.
ro
st
ra
tu
m
0
.0
3
–0
.1
2
0
.0
3
–0
.1
2
0
.0
3
–1
.0
0
.0
3
–0
.1
2
–
–
–
0
.0
3
–>
1
6
.0
0
.0
3
–0
.2
5
Fo
ns
ec
ae
a
[8
3
,3
7
8
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
s
b
ra
in
ab
sc
e
ss
F.
m
on
op
ho
ra
0
.5
0
–2
.0
0
.0
3
–0
.2
5
0
.1
2
–1
.0
0
.0
1
–0
.0
6
0
.0
6
–1
.0
–
8
.0
–6
4
.0
1
.0
–4
.0
–
F.
p
ed
ro
so
i
0
.5
0
–2
.0
0
.0
3
–0
.2
5
0
.1
2
–0
.5
0
0
.0
3
–0
.0
6
0
.0
6
–0
.2
5
–
8
.0
–3
2
.0
2
.0
–4
.0
0
.0
6
–0
.2
5
Fo
ns
ec
ae
a
sp
p
.
0
.5
0
–2
.0
0
.0
3
–0
.2
5
0
.1
2
5
–1
.0
0
.0
1
–0
.0
6
0
.0
6
–1
.0
–
8
.0
–6
4
.0
1
.0
–8
.0
–
H
or
ta
e
[3
9
6
]
T
in
e
a
n
ig
ra
,
ve
ry
ra
re
d
e
e
p
m
yc
o
si
s
H
.
w
er
ne
ck
ii
0
.1
2
–2
.0
0
.0
3
–0
.5
0
0
.0
6
–0
.2
5
0
.0
1
–0
.1
2
0
.0
6
–0
.5
–
8
.0
–6
4
.0
1
.0
–8
.0
–
N
eo
sc
yt
al
id
iu
m
[1
0
3
,4
0
0
,4
0
1
,4
0
9
]
C
u
ta
n
e
o
u
s
in
fe
ct
io
n
s
an
d
o
n
yc
h
o
m
yc
o
si
s,
ve
ry
ra
re
d
e
e
p
m
yc
o
si
s
N
.
di
m
id
ia
tu
m
0
.0
6
–1
.0
0
.0
3
–>
1
6
.0
0
.0
3
–4
0
.0
6
–3
2
–
–
0
.2
5
–3
2
.0
0
.0
6
–>
1
6
.0
0
.0
6
–2
.0
O
ch
ro
co
ni
s
[4
3
4
,4
3
7
]
P
n
e
u
m
o
n
ia
,
b
ra
in
ab
sc
e
ss
,
d
is
se
m
in
at
e
d
in
fe
ct
io
n
O
.
ga
lla
p
ov
a
0
.1
2
–1
.0
0
.0
1
–0
.5
0
0
.1
2
–2
.0
0
.0
1
–0
.1
2
–
1
6
.0
–>
6
4
.0
1
6
.0
–>
6
4
.0
1
.0
–8
.0
0
.0
3
–1
.0
O
.
ts
ha
w
yt
sc
ha
e
4
.0
0
.5
0
0
.1
2
–
–
–
>
6
4
.0
0
.2
5
–
Ph
ae
oa
cr
em
on
iu
m
[4
4
5
,4
4
6
]
Su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
ar
th
ri
ti
s,
d
is
se
m
in
at
e
d
d
is
e
as
e
P.
p
ar
as
iti
cu
m
2
.0
0
.1
2
–8
.0
0
.0
6
–0
.2
5
0
.0
3
–0
.5
0
–
–
8
.0
>
1
6
.0
0
.5
0
–2
.0
Ph
om
a
[4
5
7
,4
5
9
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
o
cu
la
r
in
fe
ct
io
n
,
ra
re
d
ee
p
m
yc
o
si
s
Ph
om
a
sp
p
.
0
.5
–1
.0
0
.2
5
–8
.0
0
.2
5
–8
.0
–
–
–
–
–
–
Py
re
no
ch
ae
ta
[4
6
2
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
k
e
ra
ti
ti
s
P.
ro
m
er
oi
4
.0
0
.5
0
4
.0
0
.5
0
0
.1
2
–
>
6
4
.0
8
.0
–
R
hi
no
cl
ad
ie
lla
[1
3
0
,4
7
8
,4
8
0
,4
8
5
]
B
ra
in
ab
sc
e
ss
R
.
m
ac
ke
nz
ie
i
1
.0
–>
1
6
.0
0
.0
1
–0
.2
5
0
.0
1
–2
.0
0
.0
1
–0
.2
5
4
.0
–1
6
.0
1
6
.0
–6
4
.0
1
.0
–8
.0
–
R
.
aq
ua
sp
er
sa
1
.0
–2
.0
0
.0
6
–0
.1
2
2
.0
0
.0
6
–0
.1
2
–
3
2
.0
–6
4
.0
8
.0
–
V
er
on
ae
a
[4
9
4
]
C
u
ta
n
e
o
u
s
an
d
su
b
cu
ta
n
e
o
u
s
in
fe
ct
io
n
,
d
is
se
m
in
at
e
d
d
is
e
as
e
V
.
bo
tr
yo
sa
8
.0
–1
6
.0
0
.2
5
–1
.0
1
.0
–8
.0
0
.0
3
–0
.2
5
4
.0
–>
1
6
.0
–
>
6
4
.0
2
.0
–>
1
6
.0
1
.0
–4
.0
A
M
B
,
am
p
h
o
te
ri
ci
n
B
;
IT
C
,
it
ra
co
n
az
o
le
;
V
R
C
,
vo
ri
co
n
az
o
le
;
P
O
S,
p
o
sa
co
n
az
o
le
;
IS
A
,
is
av
u
co
n
az
o
le
;
FC
,
ﬂ
u
cy
to
si
n
e;
FL
U
,
ﬂ
u
co
n
az
o
le
;
E
C
H
IN
O
,
e
ch
in
o
ca
n
d
in
s;
T
E
R
B
,
te
rb
in
aﬁ
n
e
;
A
B
P
M
,
al
le
rg
ic
b
ro
n
ch
o
p
u
lm
o
n
ar
y
m
yc
o
si
s.
a D
e
p
ic
ts
co
lle
ct
iv
e
M
IC
ra
n
ge
s
fr
o
m
al
l
th
e
re
fe
re
n
ce
s
m
e
n
ti
o
n
e
d
.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 3), 47–75
CMI Chowdhary et al. ESCMID/ECMM joint clinical guidelines for phaeohyphomycosis 49
Once the ﬁrst consensus was reached, the preliminary
recommendations were discussed, developed further and
ﬁnalized as a group consensus. The methods to evaluate the
quality of evidence and to reach consensus recommendations
were described previously in detail when the ﬁrst ofﬁcial
ESCMID guidelines on the diagnosis and treatment of Candida
infections were published [1–6].
The characteristic feature of phaeohyphomycosis is the
presence of melanin in the fungal cell walls, which gives a dark
colour to the hyphae, and is considered a major virulence
factor. The criteria for selecting the evidence were searching
the literature using the string ‘melanized’, ‘dark’, ‘phaeoid’ and
‘dematiaceous’ and search results were systematically
reviewed. As the clinical syndromes associated with these
fungi are common across the different pathogens (Table 2),
the ﬁrst part of this guideline presents recommendations for
each clinical entity (localized cutaneous and subcutaneous
infection, chromoblastomycosis, mycetoma, keratitis, pulmo-
nary infections, cerebral infection, disseminated disease and
allergic manifestations). Subsequently, speciﬁc issues for each
of the fungal pathogens are presented in alphabetical order.
Most recommendations in this guideline are based on
dramatic results of uncontrolled experiments, opinions of
respected authorities, clinical experience, descriptive case
studies, or reports of expert committees. In some cases, in
vitro data and animal studies are also included. Unfortunately,
much of the older literature could not be included because of
the unreliability of the non-molecular strain identiﬁcation
methods used. These guidelines highlight the fact that there is
no standard approach for treatment of phaeohyphomycosis.
Also, the reference microdilution methodologies for in vitro
antifungal susceptibility testing have not been standardized nor
are the validated MIC breakpoints that are used for
interpretation of the results for antifungal drugs against the
phaeoid fungi available. Unlike the other guidelines for fungal
infections caused by rare yeasts and the mucorales, which
recommend clear-cut therapeutic approaches [7,8], the huge
diversity of dematiaceous fungi and their host range make it
impossible to advise a uniform approach for phaeohyphomy-
cosis. Length of therapy and choice of intervention (surgery,
antifungals or both) for each clinical entity is primarily based
on the clinical presentation, the underlying condition of the
host and the initial response. The prolonged duration of
therapy in the diseases caused by phaeoid fungi generally
ranges from several weeks to months or longer. The clinical
entities and their therapeutic recommendations are given
below and summarized in Tables 1–4. Table 3 includes
recommendations for diagnostic procedures and susceptibility
testing of these diseases [9–25]. These guidelines will be
periodically updated.T
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Recommendations by Clinical Entities
Localized cutaneous infection and subcutaneous nodules
One of the common manifestations of dematiaceous fungi is
superﬁcial localized cutaneous and subcutaneous disease. Most
superﬁcial infections are secondary to trauma. Lesions
typically appear as isolated cystic or papular lesions on
exposed areas of the body, such as limbs and hands. Alternaria
spp. are the most common aetiological agent and others
include species of Exophiala spp. and Phialophora. Clinical
presentation is usually indolent, with a gradually enlarging
mass. Generally immunocompromised patients are at
increased risk of subsequent dissemination. On histopatho-
logical examination the phaeohyphomycotic cyst presents as a
single dermal lesion with minimal changes in the epidermis and
granulomatous inﬂammation with abundant giant cells. Fungal
elements such as yeast-like structures and septate hyphae can
be found in the specimen. For subcutaneous nodules in
particular, surgery alone has been effective (recommendation
AII) [12,26–32]. Cryotherapy, laser, heat and photodynamic
therapy have also been used successfully in many cases
(recommendation BIII) [33–37]. Oral antifungals, mainly
azoles, have been widely used as co-adjunctive therapies
particularly in immunocompromised patients and to prevent
dissemination (recommendation BIII) [12]. Multiple subcuta-
neous nodules have to be treated with systemic antifungal
agents. Itraconazole or voriconazole at 400 mg are recom-
mended (recommendation AIII) [38–44]. Other antifungal
agents have been used in some cases (recommendation CIII,
Table 4) [12,41,45–58].
Eumycotic mycetoma
Mycetomas are localized infections that involve cutaneous
and subcutaneous tissue, fascia and bone. Lesions consist of
abscesses, granulomata and draining sinuses from which
granules may be recovered. They may be caused by
different fungi, which produce granules of different colours,
such as Acremonium spp. (white), Aspergillus nidulans (white),
Exophiala jeanselmei (black), Leptosphaeria senegalensis (black),
Madurella grisea (black), Madurella mycetomatis (black), Neot-
estudina rosatii (white) and Pyrenochaeta romeroi (black).
Mycetoma is difﬁcult to cure and therapy includes amputa-
tion of the affected limb or large surgical excision of the
affected tissue to reduce the disease burden. However,
excision alone is rarely sufﬁcient for a complete cure. This
condition always requires surgery and prolonged systemic
antifungal therapy (recommendation AII) [59–64]. Histori-
cally, the majority of cases reported used ketoconazole or
itraconazole. Itraconazole appears to have consistent clinical
activity (recommendation AII), and ketoconazole should be
avoided because of side effects (recommendation DIII). Also,
the newer triazoles (voriconazole and posaconazole; recom-
mendation AIII) and combination therapy with terbinaﬁne or
ﬂucytosine have been used successfully (recommendation
BIII) [65–69].
Chromoblastomycosis
This is a chronic subcutaneous infection by dematiaceous fungi
characterized by the presence of muriform cells or sclerotic
bodies (medlar bodies) in tissue sections or wet preparations
of pus or scrapings. Muriform cells are thick-walled, spherical,
dark brown cells, which swell and often develop intersecting
septa in various planes. The most commonly involved fungi are
Cladophialophora carrionii, Fonsecaea compacta, Fonsecaea pedro-
soi and Phialophora verrucosa. These causative agents of
chromoblastomycosis are rarely recovered from nature but
are selectively enriched by the human host [70]. The infection
is difﬁcult to cure, and relapses are common, possibly due to
resistance development during therapy [71–76]. Overall,
several studies suggest that standard of therapy should include
itraconazole plus surgery (recommendation AII) [72–74,76]. In
a few cases of chromoblastomycosis terbinaﬁne monotherapy
and surgery have been applied successfully (recommendation
BIII) [72,75,77,78]. In addition, laser, heat and potassium iodide
therapies have also been used in the past with successful
outcome (recommendation BIII) [75,79–81]. Recommenda-
tions for refractory cases are combination antifungal therapy
including cryotherapy or surgery when possible (recommen-
dation BIII) [72,74,75,82–84]. Based on experimental and in
vitro studies the new triazole drug posaconazole is promising
and could be useful when other therapy has failed (recom-
mendation BIII) [85–88].
Keratitis
Keratitis due to dematiaceous fungi is mainly reported from
India where trauma accounts for up to 20% of cases [89–91].
The majority of patients can be treated with topical agents, the
most commonly used are 5% natamycin and topical ampho-
tericin B (0.15–0.3%) with or without topical azoles (1%) for at
least 4 weeks to several months (recommendation AII)
[89,90,92–94]. Topical azoles alone especially itraconazole
and voriconazole (1%) can also be used (recommendation BIII)
[95–97]. Severe and refractory cases require administration of
oral azoles and usually surgery including penetrating and
lamellar keratoplasty (recommendation BIII) [89,91–93]. An
intracorneal injection of voriconazole (1%) as salvage therapy
has been efﬁcient in patients not responding to topical and
systemic therapy in some cases (recommendation CIII)
[96,98].
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Pulmonary infections
These are potentially life threatening and are mainly seen in
immunocompromised patients or those with underlying lung
disease although cases in immunocompetent patients have
been reported [99–101]. A wide variety of species can be
involved and clinical manifestations include pneumonia, pul-
monary nodules and endobronchial lesions. Therapy consists
of intravenous liposomal amphotericin B or mould-active
azoles except ketoconazole for a prolonged period (recom-
mendation BIII). However, mortality rates are high in immu-
nocompromised patients if underlying host defence defects are
not resolved [12,102–107]. Solitary pulmonary nodule in
immunocompetent patients can be treated with surgery
(recommendation BIII) [12,99,108].
Cerebral infection
Cerebral abscess due to dematiaceous fungi is rare but
frequently fatal and a surprisingly high proportion of these
infections occurs in apparently immunocompetent individuals
[109–116]. These infections are spread haematogenously,
probably from an initial, presumably subclinical pulmonary
focus, although spread from the sinus or following surgery may
also occur. The neurotropic fungi are often geographically
restricted, such as Rhinocladiella mackenziei occurring in the
Middle East and Cladophialophora bantiana mainly in India.
Although most infections with Exophiala dermatitidis are
reported from East Asia the fungus is encountered worldwide.
Overall, the therapeutic studies suggest that complete excision
of brain abscesses has better outcome than only aspiration or
partial excision (recommendation AII) [109,112,117–120].
Even with antifungal therapy outcome is poor; however, single
cases suggest that voriconazole and posaconazole may provide
clinical improvement and voriconazole penetrates into brain
tissue most effectively (recommendation CII) [121–128].
Amphotericin B therapy generally has a poor outcome
(recommendation DIII) [122–124,129]. Combination therapy
including a triazole plus an echinocandin plus ﬂucytosine, which
also has in vitro activity against many of the black moulds and
achieves good brain penetration, could be the ﬁrst-line therapy
when surgery is not possible (recommendation BIII)
[12,116,130].
Other localized deep infections
These comprise mainly bone and joint infections and perito-
nitis. Recommendations can be found in Table 4 [12,131–137].
Disseminated infection
This is uncommon and reported mainly in the immunocom-
promised population [138]. Occasionally Exophiala asiatica
causes dissemination in patients without known immunodeﬁ-
ciency or risk factors and it was recently reported from China
[139,140]. There are at present no antifungal regimens
associated with improved survival in disseminated infection,
including multiple combination therapies (recommendation
CIII) [138,141–147]. Combination antifungal therapy with
adjunctive treatments has been effective in some cases of
infections with hyaline fungi and multi-resistant Scedosporium
spp. (recommendation BIII) [148–150].
Allergic fungal sinusitis
This entity is a hypersensitivity reaction, especially in immu-
nocompetent, often atopic patients, and is caused by many
species of dematiaceous fungi. The main black fungi involved
are Bipolaris, Curvularia, Exserohilum and Alternaria species.
Diagnosis depends on a histopathological demonstration of
allergic mucin with visible fungal elements. Therapy consists of
systemic steroids combined with surgical removal of the mucin
(recommendation AII) [151–154]. The role of antifungal
therapy, mostly azoles, is still under debate but may have a
steroid-sparing effect (recommendation CIII) [152,153,155].
Recent reports indicate that oral triazole therapy can reduce
symptoms of refractory sinusitis (recommendation BIII) [156–
158]. In many instances the dematiaceous fungi can be the
aetiological agents of sinus fungus balls. Surgical resection of
fungus balls is generally sufﬁcient (recommendation AII) unless
local tissue invasion of the surrounding mucosa is demon-
strated. Additional systemic antifungal drugs are indicated
when this occurs (recommendation CIII) [159].
Allergic bronchopulmonary mycosis
This mycosis caused by fungi other than Aspergillus is a rare
disease with <200 reported cases worldwide [160]. The two
most commonly implicated dematiaceous fungi are Bipolaris
and Curvularia. Analogous to allergic bronchopulmonary
mycosis due to Aspergillus, the treatment of allergic broncho-
pulmonary mycosis consists of systemic steroids (recommen-
dation BIII) [12,151,161,162]. Treatment with azoles is not yet
clearly established and therefore, not recommended (recom-
mendation DIII) [160,163].
Black Fungal Species with Clinical Relevance
During the last few decades the list of dematiaceous fungi
implicated in human infections has continued to evolve and will
further expand in line with the increase in the numbers of
susceptible patients and the employment of better diagnostic
tools. The important black fungi, their clinical manifestations,
risk factors for infection, diagnosis and treatment are discussed
along with their current taxonomical nomenclature.
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Alternaria
The genus Alternaria is a plant pathogen and is commonly
isolated from soil, air and plants [164–166]. The majority of
cutaneous and subcutaneous infections are by Alternaria
alternata followed by Alternaria infectoria, Alternaria tenuissima,
Alternaria alternatum and Alternaria tenuis [55,167].
Clinical manifestations. Clinical manifestations of Alternaria
infections are usually cutaneous or subcutaneous lesions
mainly in immunosuppressed individuals [41,52,55,167]. To a
lesser extent immunocompetent subjects can be affected
following traumatic inoculation with plant debris and/or soil
[168–171]. In cutaneous alternariosis, skin and soft tissue of
the dorsal part of the hands and feet, ﬁngers, elbows, knees
and pretibial areas are the most commonly affected [55]. Most
cases of subcutaneous alternariosis present with erythema,
desquamation of skin, crusted ulcers, erythematous macules,
yellow papules or violaceous nodules. Rarely sinusitis, keratitis
and allergic bronchopulmonary mycosis have been reported,
and disseminated infections occur with painless papulo-nodular
lesions or cutaneous nodules. Cerebral infections due to
Alternaria species are very rare [55,160,172]. The major
predisposing factor is organ transplantation, reported in 40%
of cases [39,42,55,167,173]. Bone marrow recipients are
particularly at risk of sinusitis, whereas lung transplant
recipients have a risk of cerebral infection [55,174]. In
cutaneous/subcutaneous diseases Cushing syndrome is a major
risk factor [175,176]. Other risk factors are long-term
corticosteroid therapy, surgery, diabetes, human immunode-
ﬁciency virus infection, tuberculosis, neutropenia and haema-
tological malignancies [29,31,43,47,177,178].
Diagnosis. Speciﬁc diagnosis is based on the microscopic
detection of yellowish-brown hyphae with or without budding
cells in tissue biopsies, aspirated pus, surgical drainage or skin
scrapings. Culture and microscopic examination are manda-
tory for the correct identiﬁcation of Alternaria spp. Ampliﬁca-
tion of DNA targets can be required for identiﬁcation of
uncommon Alternaria spp. [164,179].
Antifungal susceptibility and treatment. Cutaneous alternariosis
usually requires the combination of wide excisional surgery,
prolonged antifungal therapy, and reduction of immunosup-
pression [39,180]. In the case of well-delimited lesions,
excision alone can lead to a total resolution of the disease,
but antifungal therapy is required to avoid relapse. Itraconaz-
ole, voriconazole, posaconazole and amphotericin B constitute
the cornerstones of the antifungal management of cutaneous
and subcutaneous alternariosis based on clinical data available
[38,55,56,167,181]. Also, a solitary case report on the
successful use of intravenous caspofungin for the treatment
of cutaneous alternariosis has been described [39]. As clinical
trials are lacking, the optimal treatment strategy for patients
with deep-seated Alternaria infections remains unclear
[44,176]. Combination antifungal therapy can be recom-
mended in disseminated cases [159,177,182]. In vitro suscep-
tibility data suggest that the susceptibility of Alternaria species
to antifungal agents appears to be species dependent (Table 2)
[38]. Most of the species are susceptible to amphotericin B,
itraconazole, voriconazole and posaconazole, and with high
MIC values of echinocandins, ﬂuconazole and ﬂucytosine.
Terbinaﬁne also has been used successfully in the treatment of
cutaneous alternariosis [31,46,173]. The role of echinocandins
as part of combination therapy for alternariosis remains to be
clariﬁed.
Acrophialophora
The genus Acrophialophora comprises three species but only
Acrophialophora fusispora is of clinical interest. Acrophialophora
fusispora is a thermotolerant fungus with a wide distribution in
tropical and temperate regions [164].
Clinical manifestations. Only ﬁve cases of phaeohyphomycosis
have been reported so far, which include two cases of brain
abscess attributed to Acrophialophora fusispora and three other
cases involving the lung in two and cornea in one case [183–
185].
Diagnosis. This fungus is similar to Paecilomyces spp. and
sometimes misidentiﬁed as Scedosporium proliﬁcans [186] but
can be differentiated by the presence of pigmented, warted
conidiophores, basally inﬂated verticillate phialides and pig-
mented fusiform conidia ornamented in spiral bands.
Antifungal susceptibility and treatment. Due to the small number
of cases reported, the optimal treatment and management of
these infections are unknown. The isolates tested have shown
variable susceptibility to itraconazole, voriconazole, posaco-
nazole, amphotericin B and resistance to echinocandins.
Response in vivo has been unpredictable [183–185].
Aureobasidium
Aureobasidium is a genus of black yeasts that ubiquitously
colonize smooth surfaces of plant leaves, glass and rocks, and
may contaminate metal, glassware and tubing systems in the
hospital [187]. These fungi are commonly found as contam-
inants in the clinical laboratory. Clinically signiﬁcant species are
Aureobasidium pullulans, Aureobasidium proteae and Aureobasid-
ium mansoni, all of which are associated with cerebral
phaeohyphomycosis [164,188].
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Clinical manifestations. Aureobasidium pullulans has an afﬁnity for
synthetic materials and surgically implanted silastic devices, as
the fungus has been isolated from indwelling peritoneal dialysis
catheters and central venous lines [189–193]. In severely
compromised patients deep infections are encountered, and
the fungus has been isolated from blood, bronchoalveolar
lavage, lymph nodes, splenic abscess or cerebrospinal ﬂuid
[187,194–203]. Infections are caused mostly by traumatic
inoculation of the skin or eye, and intrathecal administration of
cytotoxic drugs [204–210].
Diagnosis. Black yeasts are observed by microscopy. Classiﬁ-
cation of this fungus can be done easily by conventional
methods and also by DNA sequencing.
Susceptibility testing and treatment. No standard treatment
exists for Aureobasidium infections but amphotericin B is
recommended because it has been successfully used to treat
systemic infection, meningitis and peritonitis [190–192].
However, two cases of fungaemia reported to have ampho-
tericin B treatment failure are on record [187,197]. Other
alternative treatment options which are reported to be
effective in localized infections could be ﬂuconazole and
ﬂucytosine [192,199]. In vitro studies revealed that this
organism showed variable degrees of susceptibility to com-
monly used antifungals (Table 2) [211]. Apart from ampho-
tericin B in invasive cases, voriconazole could be added
concomitantly because it completely cured a chronic menin-
gitis case caused by Aureobasidium proteae [188].
Bipolaris
Bipolaris spp. are ubiquitous in nature and found in soil and
decaying matter [212]. The commonest species in human
infections are Bipolaris australiensis, Bipolaris hawaiiensis and
Bipolaris spicifera [12,213]; however, these three species have
recently been transferred to Curvularia [214]. Bipolaris spp.
previously classiﬁed as Drechslera or Helminthosporium are
emerging as important aetiological agents of phaeohyphomy-
cosis in humans [164].
Clinical manifestations. Bipolaris spp. are associated with serious
infections in immunocompetent and immunocompromised
hosts, such as pansinusitis [215], endophthalmitis and orbital
cellulitis [216,217], necrotizing pneumonia and allergic bron-
chopulmonary mycosis [160,162,218], peritonitis [219],
ascending aorta endarteritis [220] and encephalitis
[221,222]. Dissemination to the central nervous system via
the nasal sinuses has been described [114,223–225]. Dissem-
ination to other deep sites may occur in debilitated or
compromised patients such as those having undergone either
organ transplantation or other surgical procedures [226–230].
Superﬁcial disease involving cutaneous, subcutaneous and
corneal regions afﬂicts mainly immunocompetent patients
[115,231–233].
Diagnosis. Diagnostic procedures of cutaneous and invasive
infections are summarized in Table 3 and are similar for most
black fungi. Molecular identiﬁcation based on PCR and
sequencing of the internal transcribed spacer (ITS) and D1/
D2 regions of rDNA is recommended for accurate identiﬁca-
tion [234]. Direct detection of Bipolaris DNA by PCR has been
reported [235,236]. As with all fungi in this class, the Fontana–
Masson stain is helpful for diagnosis [237].
Antifungal susceptibility and therapy. Treatment involves a
combination of surgical debridement and antifungal treatment,
typically with amphotericin B or an azole [238–241]. With the
exception of ﬂuconazole and ﬂucytosine, amphotericin B,
itraconazole, posaconazole and voriconazole showed good
activity against species of Bipolaris [213,242]. Surgical inter-
ventions such as removal of foreign objects, catheter tips or
sinus debridement are usually necessary as adjunctive therapy,
especially in localized infections and those associated with
foreign implants [243,244].
Chaetomium
The genus Chaetomium is a large genus of saprobic ascomy-
cetes including >180 species. Chaetomium species are generally
found in warm, dry, cellulose-rich media, such as animal dung,
straw, seeds, plant debris, bird feathers and many other
substrates [245,246]. They are rarely implicated in human
disease; the clinically signiﬁcant species include Chaetomium
globosum, followed by Chaetomium strumarium, Chaetomium
atrobrunneum, Chaetomium funicola and Chaetomium perlucidum
[247–255].
Clinical manifestations. The spectrum of mycoses caused by
Chaetomium species includes onychomycosis, chromoblasto-
mycosis and sinusitis in immunocompetent individuals
[249,253], and empyema, pneumonia, and fatal disseminated
cerebral disease in immunocompromised hosts and intrave-
nous drug users [247,248,250–252,254,255]. The majority of
reports have involved patients with haematological malignan-
cies and/or immunosuppression secondary to bone marrow or
solid organ transplantation [102,248,252,254,255].
Diagnosis. Diagnostic procedures are similar to those previ-
ously described. The main characteristic of Chaetomium species
is the presence of hairs or setae covering the ascomata. They
are differentiated by the size and shape of ascomata, the type
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of setae they possess, and the size and shape of their brownish
ascospores [143,164,256].
Susceptibility testing and treatment. Most patients with reported
invasive disease received either conventional or lipid-based
amphotericin B empirically during their treatment course
[247–255]. Chaetomium perlucidum isolates have low MICs of
amphotericin B, itraconazole, voriconazole and posaconazole,
but high MICs of caspofungin. Amphotericin B had varied
susceptibility proﬁles while itraconazole and voriconazole
exhibited good activity against Chaetomium globosum
[143,257,258].
Cladophialophora
The genus includes neurotropic fungi such as Cladophialophora
bantiana and Cladophialophora modesta causing mainly brain
infections [259]. While Cladophialophora bantiana is reported
worldwide, a general preference for warm climates with high
humidity is apparent [260]. Cladophialophora carrionii is
prevalent in dry countries and desert zones, and other rarely
reported species Cladophialophora devriesii and Cladophialophora
arxii cause disseminated disease, while Cladophialophora boppii,
Cladophialophora emmonsii and Cladophialophora saturnica cause
mild cutaneous infections [164,245,261–263].
Clinical manifestations. Human infections, due to Cladophialo-
phora range from mild cutaneous lesions to fatal cerebral
infection. In a review in 2004, Cladophialophora bantiana was
the most common species responsible for cerebral disease and
accounted for 48 of 101 cases of cerebral phaeohyphomycosis
[127]. Single lesions were present in the majority of cases of
brain abscess. Also, no evidence of dissemination outside the
central nervous system has been observed. Patients with
central nervous system phaeohyphomycosis are often immu-
nocompetent and have no known underlying diseases
[123,124,264,265]. These species also cause superﬁcial and
subcutaneous diseases. Most of the aetiological agents produce
only localized disease restricted to skin and subcutaneous
tissue. Chromoblastomycosis due to Cladophialophora is mainly
caused by Cladophialophora carrionii [12,266]. Risk factors or
underlying diseases associated with infection due to
Cladophialophora are organ transplantation, diabetes, systemic
lupus erythematosus, pulmonary tuberculosis, primary
immunodeﬁciency of unknown origin, recurrent cytomegalo-
virus viraemia, pneumonitis, neutropenia and nephrectomy
[105,126,128,267,268].
Diagnosis. Cladophialophora is a genus related to black yeast--
like fungi but in routine cultures it grows strictly monomor-
phically as a mould with long, delicate, branching chains of
hydrophobic conidia and lacking yeast cells [164]. In cerebral
phaeohyphomycosis and other infections a KOH preparation
of pus from the lesion may show lightly pigmented yeast-like
forms or more often short chains of spores and hyphae.
Histopathology is essential for conﬁrmation of subcutaneous
infections. Culture is recommended and for species identiﬁ-
cation, sequencing of ITS regions of rDNA is most appropriate
[245]. Although there are no speciﬁc clinical or radiological
features for the diagnosis of cerebral phaeohyphomycosis, a
computed tomography scan of the cranium often reveals
unilateral well-circumscribed single or multiple mass lesions
localized within the cerebral cortex [117,260,269]. Purulent
meningitis, with or without brain abscess, may also be seen
[265].
Susceptibility testing and treatment. When possible, complete
surgical removal of the encapsulated abscess combined with
antifungal therapy is recommended, but so far success in
treating cerebral phaeohyphomycosis due to Cladophialophora
is limited regardless of the immune status of the patient (>70%
mortality) [12,127]. Adding antifungal monotherapy or com-
bination therapy might improve survival [270,271]. When
there are multiple cerebral abscesses and surgery is not
practicable, combination therapy with amphotericin B, ﬂucy-
tosine, caspofungin and terbinaﬁne, or an extended spectrum
triazole, has been proposed as a regimen [12,128]. Itraconaz-
ole and posaconazole had the best activity in vitro, while
voriconazole has better central nervous system penetration
and better bioavailability [272–275]. Echinocandins and
amphotericin B have shown also activity in vitro [87,123]. The
newer drug isavuconazole reveals low MICs for Cladophialo-
phora carrionii. In murine models of Cladophialophora bantiana
infections, the combination of the three drugs ﬂucytosine,
micafungin and posaconazole was the only therapy that
prolonged survival time [276].
Curvularia
The genus Curvularia comprises nearly 100 species. Most are
saprobes in soil, on dead plant material or plant pathogens
mainly infecting grasses [212]. The clinically relevant species
are Curvularia aeria, Curvularia geniculata/Curvularia senegalensis
and Curvularia lunata; less frequently implicated species are
Curvularia brachyspora, Curvularia clavata, Curvularia inaequalis,
Curvularia pallescens and Curvularia verruculosa [164,212,277].
Clinical manifestations. More commonly, species of Curvularia
cause allergic sinusitis [278,279], but they can disseminate to
the brain even in immunocompetent patients [113]. Other
manifestations include subcutaneous infections following trau-
matic implantation [280,281], onychomycosis [282], keratitis
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[283,284], endophthalmitis [285,286], mycetoma [287], inva-
sive sinusitis [288,289], peritonitis [290,291], invasive cerebral
infections [292,293], endocarditis [294] and disseminated
infections [295–297].
Diagnosis. Colonies of Curvularia are blackish, expanding and
hairy; the conidiophores are erect and the conidia are
ellipsoidal, brown, usually curved and generally with three or
four septa. Recent studies have demonstrated that molecular
conﬁrmation of species is usually required by sequencing the
ITS regions of rDNA and the glyceraldehyde-3-phosphate
dehydrogenase gene [164,212,277,298].
Antifungal susceptibility and treatment. The in vitro antifungal
susceptibility of different clinical isolates of Curvularia has been
determined in several studies (Table 2) [113,277,284,299]. In
general, amphotericin B showed potent in vitro activity and
triazoles and echinocandins had less in vitro activity. Clinical
experience with the treatment of Curvularia infections is scarce
and mainly based on a few case reports where amphotericin B
and azoles have been the most frequently used drugs in
monotherapy or combination therapy with variable results
(Table 4) [110,279,280,286,293,295,297,300,301].
Exophiala
The genus Exophiala comprises the most clinically relevant
black yeasts, often isolated from environmental substrates,
including soil, wood and other plant material [164,298]. The
species commonly involved in human infections are Exophiala
dermatitidis, Exophiala xenobiotica and Exophiala oligosperma,
followed by Exophiala lecaniicorni, Exophiala phaeomuriformis,
Exophiala jeanselmei, Exophiala bergeri, Exophiala mesophila,
Exophiala spinifera, Exophiala xenobiotica and Exophiala oligosper-
ma [302–304]. Although distributed worldwide, Exophiala
dermatitidis, a neurotropic agent, is reported mainly from Asia,
whereas Exophiala spinifera is reported from various parts of
the world as the causative agent of phaeohyphomycosis and
chromoblastomycosis [259,264,304,305].
Clinical manifestations. Most of the infections caused by
Exophiala are cutaneous and subcutaneous [306–308] whereas
fatal systemic infections can occur, including rare cerebral
infections [139,140,164,298,309]. Exophiala species produce
pustules or verrucous plaques in the skin or subcutaneous
tissue. These lesions can enlarge and impair mobility but rarely
disseminate to the internal organs [35,305,310,311]. Chromo-
blastomycosis or eumycotic mycetoma is rarely caused by this
genus [60,74]. Besides subcutaneous infections, this species
can cause pulmonary colonization of the lungs in patients with
cystic ﬁbrosis [312] and brain abscess and disseminated,
eventually fatal, disease in patients without recognized under-
lying diseases [304,313,314]. Disseminated disease generally
affects elderly and immunosuppressed patients such as
individuals with AIDS or those on prolonged use of immuno-
suppressive drugs, chemotherapy treatment or systemic
corticosteroids [267,315–317]. Additionally, intestinal coloni-
zation by the fungus has been reported [318,319].
Diagnosis. The histological characteristics of Exophiala for a
cutaneous deep fungal infection include epidermal hyperker-
atosis, hyperplasia, acanthosis, pseudoepitheliomatous and
intraepidermal pustule formation. Pigmented fungal elements
can be detected most frequently in areas of inﬂammation,
within or adjoining to multinucleate giant cells. Diagnostic
techniques are shown in Table 3. Molecular methods of
detection and classiﬁcation have also been reported [303,320].
Susceptibility testing and treatment. Apart from surgical resec-
tion, which in some cases is curative, treatment requires
antifungal agents such as itraconazole or terbinaﬁne alone or in
combination [267,321,322]. As an alternative to the prolonged,
expensive pharmacological treatments, some authors propose
Mohs micrographic surgery as an effective therapeutic option
with the important beneﬁt of minimal tissue loss [26]. Other
antifungal agents have also been used, and brain and dissem-
inated infections are infections that are difﬁcult to treat
[141,323–333]. In vitro susceptibility studies demonstrated
variable activity of posaconazole, itraconazole, voriconazole
and amphotericin B [334–338]. In animal models of dissemi-
nated infection by Exophiala dermatitidis posaconazole was
more effective than amphotericin B and itraconazole [339].
Exserohilum
The anamorphic genusExserohilum comprises around 35 species,
which are common saprobic fungi on plant debris [164]. Three
species Exserohilum rostratum, Exserohilum longirostratum and
Exserohilum mcginnisii have been reported in the past as
opportunistic pathogens for humans. However, several molec-
ular studies have demonstrated that they belong to a single
species, Exserohilum rostratum being the accepted one [340].
Clinical manifestations. Exserohilum is a rare clinically signiﬁcant
pathogen causing invasive infections mainly in immunocom-
promised patients [222,341–356], keratitis [357–361] or
localized infections in immunocompetent individuals usually
after accidental inoculation [362–364]. The risk factors for
Exserohilum infections include aplastic anaemia [345,365] and
haematopoietic stem cell transplantation [341,356].
Recently, Exserohilum rostratum has been implicated in a
fungal meningitis outbreak that was traced back to contami-
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nated steroid injections [366–369]. As of 23 October 2013
there were 718 cases of fungal meningitis, stroke due to
presumed fungal meningitis, and/or spinal or paraspinal
infections; 33 cases of peripheral joint infections and 64 deaths
(http://www.cdc.gov/hai/outbreaks/meningitis-map-large.html,
accessed 9 December 2013).
Diagnosis. Exserohilum species are mainly identiﬁed by the
conidial morphology when growing in its natural substratum
[164]. In vitro identiﬁcation is more difﬁcult, the conidia tending
to be smaller and the isolates often losing the ability to
sporulate. At the generic level, the most useful microscopic
characteristics are the conidial shape with the presence of a
protruding scar or hilum. Sequencing of the ITS region of
rDNA for molecular identiﬁcation has been used. In the
context of the above mentioned outbreak, species-speciﬁc
real-time PCR assays were developed for rapid molecular
diagnosis [370,371].
Antifungal susceptibility and treatment. There are limited data on
the treatment of infections due to Exserohilum. Experience
from the recent meningitis outbreak [368] and case reviews of
sinusitis and cutaneous infections by these fungi reveal
successful outcomes with amphotericin B [341,346,372] and
more recently with itraconazole and voriconazole [347,353].
Based on historical data, amphotericin B might be the ﬁrst
choice in severe infections [340,373,374] but an expert group
coordinated by the US Centers for Disease Control advised
voriconazole because of its excellent pharmacokinetics/phar-
macodynamics in cerebral infections [366,375]. However,
clinical failures with voriconazole have been reported [376].
In vitro studies showed itraconazole, posaconazole and ampho-
tericin B to be the most potent followed by voriconazole
[340,375]. Animal models of Exserohilum central nervous
system infection have not yet been developed for therapeutic
and prophylactic studies [377].
Fonsecaea
Fonsecaea is one of the classical genera of fungi causing
human chromoblastomycosis. A small group of three closely
related species include Fonsecaea pedrosoi, Fonsecaea mono-
phora and Fonsecaea nubica [378]. Fonsecaea particularly
occurs in tropical climate zones, especially South America
and Japan [379–381]. Most cases outside endemic zones are
assumed to have been imported. However, cases that were
likely to be autochthonous were reported even in northern
Europe [382]. Other Fonsecaea species are saprobes in the
environment, and occasionally cause infections in animals
[383].
Clinical manifestations. The classical presentation of chromo-
blastomycosis caused by Fonsecaea is similar to that described
previously above [74]. The disease is probably acquired by
traumatic inoculation of plant debris and possibly hydrocar-
bon-rich plant material, such as coconut shells, which are
preferentially infested by Fonsecaea species [384]. Fonsecaea
infections other than chromoblastomycosis are rare and
mainly concern brain infections by Fonsecaea monophora
[385–387]. The portal of entry of these infections is unknown
but dissemination from a pulmonary focus is likely.
Diagnosis. Fonsecaea species are recognized by poorly differ-
entiated conidiophores apically producing short, branched
chains of conidia [74,298,370]. For species distinction,
sequencing of rDNA ITS regions is necessary [378,386].
Genus-speciﬁc PCR for detection of Fonsecaea species has
been applied [71,388]. Detection of 1,3-b-D-glucan was used to
diagnose and monitor therapy against cerebral phaeohyph-
omycosis by Fonsecaea monophora in a transplant recipient
[125].
Susceptibility testing and treatment. Therapy for chromoblasto-
mycosis has already been commented on (Table 4). Surgery
plus antifungal therapy is the standard of therapy. In addition,
combination therapy with itraconazole plus terbinaﬁne or
ﬂucytosine has been successfully used in severe disease
[72,83]. In vitro susceptibility data of these species revealed
lowest MICs for posaconazole followed by itraconazole,
voriconazole, terbinaﬁne, amphotericin B and caspofungin
[378]. A refractory case of chromoblastomycosis caused by
Fonsecaea monophora failed treatment with itraconazole and
terbinaﬁne. Photodynamic therapy and combination therapy
with voriconazole plus terbinaﬁne led to improvement of the
lesions [37].
Hortaea werneckii
The melanized, polymorphic and yeast-like fungus Hortaea
werneckii, previously known as Exophiala werneckii or Cladospo-
rium werneckii, is the black yeast responsible for tinea nigra.
Hortaea werneckii is best known from tropical climates and lives
in saline environments such as seawater and natural or
man-made saltpans [389,390]. Most cases of infection originate
from rural areas in tropical and humid regions characterized by
abundant vegetation and had close contact with plants and
grasses with substrata of high salinity.
Clinical manifestations. Tinea nigra is a superﬁcial mycosis of
one or both hands and sometime affects the sole. The disease
has no preference for age or sex, with cases equally occurring
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in adults and children, and males and females [391–393]. Most
cases are unilateral but bilateral infections can be observed
[394], probably resulting from autoinoculation. The ﬁrst
human case not involving the skin was reported from an
immunocompromised patient with endophthalmitis following
cataract surgery [395]. Hortaea werneckii has been recovered
from blood and splenic abscess of two patients with acute
myelomonocytic leukaemia [396].
Diagnosis. Conidia of Hortaea werneckii appear as pigmented
yeast cells with a dark central septum, the outer wall later
becoming thick-walled and heavily pigmented. Conidia ﬁnally
germinate with hyphae resulting in yeast-like colonies that
gradually change into ﬁlaments. Molecular identiﬁcation of
Hortaea werneckii has been reported [388,390,397].
Susceptibility testing and treatment. The treatment of tinea nigra
is simple and effective. Most cases resolve with only keratin-
olytic agents like urea, salicylic acid and Whitﬁeld ointment,
applied once or twice a day [391]. In vitro antifungal suscep-
tibility testing showed variable MICs of itraconazole, vorico-
nazole, posaconazole, isavuconazole and amphotericin B (Meis
J.F., unpublished data). There are reports available of high MICs
of this fungus to amphotericin B, ﬂuconazole, ﬂucytosine and
caspofungin [396].
Neoscytalidium dimidiatum
Neoscytalidium dimidiatum (formerly Scytalidium dimidiatum) is a
known plant pathogen in tropical areas that can also be found
in soil and wood and can infect humans [398,399]. Scytalidium
hyalinum, previously considered a non-pigmented species
similar to Neoscytalidium dimidiatum is in fact only a mutant
variant [400]. The fungus is endemic in tropical and subtropical
areas of South America, the Caribbean, Asia and Africa but has
been increasingly reported from other non-endemic regions
owing to immigration and travel [401]. It was reported that in
Jamaica up to 40% of the population suffer from this infection
[402].
Clinical manifestations. Neoscytalidium dimidiatum causes mainly
onychomycosis and tinea pedis, and in endemic areas may rival
dermatophytes as the leading cause of superﬁcial fungal
infection. This fungus most often causes chronic superﬁcial
infections of the skin and nails, clinically resembling dermat-
ophytosis [399,403]. Rarely mycetoma, subcutaneous lesions,
cerebral infections, fungaemia and other deep-seated infec-
tions mainly affecting immunocompromised patients [399]
have also been reported. Invasive infections have been seen
mostly in immunosuppressed patients [399,401,404]. The
underlying conditions reported are similar to those of other
opportunistic invasive mycoses.
Diagnosis. Traditionally, the fungus has been characterized by
producing dark arthroconidia when grown in culture whereas
in older cultures some isolates developed a picnidial form
called Nattrassia mangiferae (formerly Hendersonula toruloidea)
[405]. However, molecular studies have demonstrated that
they are two different species, and Nattrassia mangiferae is now
accommodated in a different genus with non-pathogenic
species [406]. Neoscytalidium dimidiatum is distinguished from
dermatophytes by its characteristic sinuous, irregular hyphal
appearance and by brown pigmentation on direct microscopy
of cutaneous specimens, its fast-growing colonies, and its
sensitivity to cycloheximide [401]. On microscopy of cultures,
characteristic pigmented hyphae and long chains of bar-
rel-shaped arthroconidia are seen. In deeper tissue the fungus
has been described as producing yeast-like cells with short
hyphae [404].
Susceptibility testing and treatment. Antifungal therapy with
amphotericin B, voriconazole, posaconazole or ketoconazole
has been used with variable results [399–404,407,408]. In vitro
studies have shown that amphotericin B was the most active
drug followed by terbinaﬁne, whereas voriconazole and
posaconazole showed less activity [400,409]. The best treat-
ment of systemic infections by this fungus is unknown;
however, in a murine model, amphotericin B, voriconazole
and posaconazole had efﬁcacy in the treatment of a dissem-
inated infection [410].
Ochroconis
Ochroconis encompasses several species including Ochroconis
constricta, Ochroconis gallopava, recently transferred to the
new genus Verruconis, and Ochroconis humicola [136,144,411].
Members of the genus have been isolated worldwide from
soil, thermal springs, decaying vegetation, in chicken
litter and the efﬂuents of thermal nuclear reactors
[101,412–417]. Although the organism has a worldwide
distribution, many cases of human infections have been
described in the southeastern USA [418,419]. Its exact
mode of transmission is unclear, but it is hypothesized that
Ochroconis might be acquired from penetrating trauma or via
inhalation of conidia [70,420,421]. Although Ochroconis spp.
have traditionally been regarded as a cause of deep
infections in birds and other animals there have been
multiple reports implicating these fungi, particularly Verruc-
onis gallopava and Ochroconis constricta, as pathogens in
humans [104,144,422–427].
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Clinical manifestations. The majority of these reports have been
in two patient populations: those that have received trans-
plants [415,423,424,426–431], and those with haematological
malignancies undergoing chemotherapy [418,419,422,432].
Infections in these two groups presented as a combination of
both pulmonary and extra-pulmonary disease, particularly
involving the brain, spleen, skin and other organ sites. Although
a number of patients with extra-pulmonary disease have
survived [101,433], it is more frequently associated with poor
clinical outcomes [418,422,424,426]. Other risk factors are
HIV and chronic granulomatous disease [144,420,434]. The
minority of cases of Ochroconis infections have been in
immunocompetent patients [435,436].
Diagnosis. The colonies of Ochroconis species are brown-olive,
and have a velvety texture. Microscopically, they are charac-
terized by brown septate hyphae, unbranched conidiophores
with apical denticles arranged sympodially, and club-shaped
conidia with one to three transverse septa [164,411]. The
paucity of Ochroconis infections in humans has two potential
consequences. First, clinicians may fail to consider it in their
differential diagnosis. Second, the microbiology laboratory
may mistakenly dismiss the organism as a contaminant, rather
than acknowledging it as a true pathogen [127,413,418].
Similar to other black fungi, sequencing of ITS and D1/D2
regions of rDNA can be used for molecular identiﬁcation
[234].
Susceptibility testing and treatment. Due to the high mortality
rate reported in patients (estimated at 50%), proper recog-
nition and treatment of Ochroconis infections are paramount
[426,430]. Several studies suggest that posaconazole and
itraconazole may be an optimal therapy for Ochroconis
infection, with amphotericin B and voriconazole as valid
alternatives. Flucytosine and ﬂuconazole are the least effective
drugs [423,427,430,434]. Ochroconis gallopava has low MICs for
most antifungal drugs with terbinaﬁne, posaconazole and
voriconazole showing the best in vitro activity [434,437].
Phaeoacremonium
The genus Phaeoacremonium initially accommodated species
with features similar to those seen in both Acremonium and
Phialophora [406]. A recent morphological and molecular
characterization of the genus using b-tubulin sequences [438]
has more clearly deﬁned the genus and provided differential
features for clinically signiﬁcant species. Human pathogens
include Phaeoacremonium parasiticum (obsolete Phialophora
parasitica), Phaeoacremonium alvesii, Phaeoacremonium amste-
lodamense, Phaeoacremonium griseorubrum, Phaeoacremonium
krajdenii, Phaeoacremonium rubrigenum, Phaeoacremonium inﬂat-
ipes, Phaeoacremonium tardicrescens and Phaeoacremonium ven-
ezuelense [30,438–440].
Clinical manifestations. Recently, Phaeoacremonium infections
have been increasingly reported in humans including subcuta-
neous abscesses, cysts, or chronic or acute osteoarthritis and
disseminated infection mostly in immunocompromised
patients (solid organ transplantation and haematological
diseases) [28–30,441–443]. Colonization of cracked skin on
the extremities has also been described [438]. In the majority
of cases, a preceding trauma leading to inoculation from the
environment was reported [30,442,443]. In immunocompro-
mised patients with disseminated infections, endocarditis, brain
abscess and fungaemia have been reported [12,438,440].
Diagnosis. Infections by Phaeoacremonium are diagnosed by
biopsy of the cysts. Direct examination reveals medium brown
hyphae, which become pale brown to hyaline and verrucous in
the aspirated pus, biopsy material or skin scrapings [30,164].
The phialides have a funnel-shaped collarette and show a wide
variety of conidia with diverse forms, including ellipsoidal,
obovate, cylindrical or allantoid (sausage-like) [438,439]. PCR
amplifying ITS regions of rDNA followed by sequencing was
shown to be able to detect and identify species of Phaeoacre-
monium [444].
Susceptibility testing and treatment. The most active drugs in
vitro against Phaeoacremonium parasiticum isolates were voric-
onazole, posaconazole and itraconazole whereas reduced
susceptibility to amphotericin B was reported [445,446].
When possible, complete surgical removal of the encapsulated
abscess combined with antifungal therapy such as posaconaz-
ole and itraconazole is the recommended treatment [28–30].
However, antifungal therapy for infections caused by some of
the species of Phaeoacremonium in immunocompromised hosts
is at present unsatisfactory [438,440,441].
Phoma
Phoma species are ubiquitous saprobes on plant material found
worldwide [164,447]. Of the more than 200 species of Phoma
currently accepted, fewer than 10 species have occasionally
been found in human infections [164,448].
Clinical manifestations. Phaeohyphomycosis caused by Phoma
has been sporadically described in the literature. Most
reported cases are subcutaneous [449–456] and ocular
infections [457,458]. Systemic infection with Phoma spp. is
generally seen in severely immunocompromised patients and
generally has a poor outcome [459–461]. Often the aetiolog-
ical agent is not identiﬁed to the species level. The risk factors
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 3), 47–75
60 Clinical Microbiology and Infection, Volume 20 Supplement 3, April 2014 CMI
or underlying diseases associated with Phoma infections may
include diabetes mellitus, corticosteroid therapy and cancer
chemotherapy [450,456,459–461].
Diagnosis. Phoma species produce slow-growing, dark-grey-ol-
ive, or dark-brown colonies. The fungus produces ostiolated
fruiting bodies known as pycnidia and numerous, small, asexual
conidia. Pycnidia are black, globose, subglobose, or pyriform
and either submerged or on the surface of agar. Conidia
(pycnidiospores) are produced from the phialides that line the
inner wall of pycnidia and are hyaline, one-celled, elliptical, rod
shaped or curved [164,460]. A PCR assay for detecting Phoma
exigua DNA in deparafﬁnized lung biopsy material has been
developed [459].
Susceptibility testing and treatment. Excision of phaeomycotic
cysts without antifungal treatment is usually curative. For the
treatment of cutaneous lesions triazoles (itraconazole and
voriconazole) [451,457] and amphotericin B [450] are recom-
mended. In vitro susceptibility data on Phoma species is based
on sporadic case reports with itraconazole and voriconazole
MICs ranging from 0.25 to 8 mg/L and amphotericin B MICs
from 0.5 to 1 mg/L [457,459].
Pyrenochaeta
Pyrenochaeta is a genus that comprises pycnidial coelomycetes
that are widely distributed in the environment, being found in
soil, on wood and on plant debris and also as plant pathogens
[462]. The species implicated in human infections include
Pyrenochaeta keratinophila, Pyrenochaeta unguis-hominis, Pyreno-
chaeta romeroi and Pyrenochaeta mackinnonii [463–468]. In a
recent phylogenetic study based on the analysis of large
subunit, ITS, small subunit, b-tubulin and chitin synthase 1
sequences, Pyrenochaeta romeroi and Pyrenochaeta mackinnonii
were accommodated in the new genera Medicopsis and
Nigrograna as Medicopsis romeroi and Nigrograna mackinnonii,
respectively [469].
Clinical manifestations. Pyrenochaeta keratinophila and Pyrenocha-
eta unguis-hominis are rarely reported as agents of keratitis and
onychomycosis, respectively [464,465]. Pyrenochaeta romeroi
and Pyrenochaeta mackinnonii have a higher clinical relevance as
agents of mycetoma and subcutaneous infections in tropical
areas [462,466–472].
Diagnosis. Colonies grow fairly rapidly, and are ﬂat, velvety or
ﬂoccose and produce dark olive-grey aerial hyphae with an
olivaceous-black reverse. Pycnidia are produced after 2–
3 weeks and are submerged, ostiolate, olivaceous to black,
spherical to pyriform, with thick walls, and often covered with
erect, stiff, dark hyphae. Conidia are produced from ampul-
liform phialides lining the innermost pycnidial wall and oozing
out of the ostiolum in slimy drops, and are hyaline, one-celled
and ellipsoidal to bacilliform [164,473]. Sequencing of ITS and
D1/D2 regions of rDNA was successfully used for molecular
identiﬁcation [234].
Susceptibility testing and treatment. No standard therapy is
available for infection with Pyrenochaeta and little is known
about the relation between MIC and clinical outcome in this
disease. Itraconazole has so far been used in the treatment of
cases with mycetoma due to Pyrenochaeta romeroi [182].
Ketoconazole, itraconazole and terbinaﬁne appear active in
vitro against Pyrenochaeta romeroi, although systemic ketoco-
nazole would not be the ﬁrst choice due to unfavourable side
effects [473].
Rhinocladiella
The genus Rhinocladiella is a small, polyphyletic genus compris-
ing a few clinically signiﬁcant species, Rhinocladiella aquaspersa,
Rhinocladiella similis, Rhinocladiella basitona, Rhinocladiella mac-
kenziei and Rhinocladiella obovoideum [164,474]. Rhinocladiella
mackenziei and Rhinocladiella obovoideum are the neurotropic
fungi affecting only the central nervous system [122,474–476].
Rhinocladiella mackenziei has never been isolated from the
environment so the natural niche of this organism remains
unknown [477]. Most of cases are restricted to the Middle
East, Persian Gulf, Somalia and Pakistan [118,120,130,478,479].
Rhinocladiella aquaspersa is an agent of chromoblastomycosis
reported from South America, and Rhinocladiella similis and
Rhinocladiella basitona are occasional opportunists [480–482].
Clinical manifestations. Most patients (60%) with Rhinocladiella
mackenziei brain abscess presented with solitary brain
abscesses and the remainder had multiple brain lesions
[109]. Among all reported cases of Rhinocladiella mackenziei
infections, 25% of patients had no reported underlying
conditions [130,477,479]. Diabetes mellitus was the predom-
inant risk factor seen in some patients followed by solid organ
failure and/or transplant [120,130,477–484]. Rhinocladiella
mackenziei infections are associated with poor outcome and
nearly 100% mortality in both immunocompetent and immu-
nocompromised individuals despite surgical intervention and
antifungal therapy [12,122,130]. Nine cerebral cases due to
Rhinocladiella obovoideum, of which ﬁve were fatal, despite
administration of amphotericin B in three of them, have been
reported so far [482].
Diagnosis. General diagnostic recommendations for cerebral
infections are stated in previous sections. These species appear
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in culture as olive dark colonies that onmicroscopic examination
show erect, thick-walled and darkly pigmented conidiophores
that give rise to conidia only at their distal portions [298,474].
Deﬁnitive identiﬁcation of the species requires sequencing of ITS
and or D1/D2 regions of the rDNA gene [118].
Susceptibility testing and treatment. There is no standard
therapy for cerebral infections and surgical drainage as
opposed to aspiration alone did not improve survival. Medical
treatment mostly involved high-dose lipid amphotericin B,
itraconazole and ﬂucytosine, or a combination of these drugs
[118,120,122,130,477–484]. In vitro antifungal susceptibility
studies of the most common pathogenic species showed that
this organism has high MICs to amphotericin B and echino-
candins, and low MICs to itraconazole, posaconazole and
voriconazole [130,478,485]. There are many reported fatal
cases of cerebral abscess where patients failed to respond to
antifungal therapy with amphotericin B [109,130,480]. A single
case of successful treatment of Rhinocladiella mackenziei brain
abscess was reported in which the patient showed improve-
ment after switching from itraconazole to posaconazole [122].
The in vitro data are also consistent with animal studies of a
murine model of Rhinocladiella mackenziei cerebral phaeohyph-
omycosis, where posaconazole was found to be superior to
amphotericin B and itraconazole and reduced the brain fungal
burden [121].
Veronaea
The genus Veronaea, deﬁned by its type species Veronaea
botryosa, is a small group containing several opportunistic species
infecting vertebrates [164]. Veronaea botryosa is an environmen-
tal fungus but with a currently undiscovered ecological niche.
The phylogenetically nearest neighbours ofVeronaea botryosa are
found in Exophiala species inhabiting water and causing oppor-
tunistic infections in waterborne animals [245].
Clinical manifestations. The clinical presentation of the infection
is a cutaneous lesion or nodular subcutaneous infection,
resembling that of chromoblastomycosis, with muriform cells
in tissue butwith a strong tendency to disseminate. The infection
has been described in both immunocompetent patients
[85,486–492], and those with debilitated immunity such as liver
[40] and heart transplant recipients [493].
Diagnosis. Veronaea botryosa is readily recognizable by its
microscopical morphology. Its large, erect conidiophores with
sympodial, uni-septate conidia on ﬂat scars give easy clues for
identiﬁcation in culture [164,298]. Molecular identiﬁcation using
sequencing of the ITS rDNA region is applicable [494].
Antifungal susceptibility and treatment. Published cases of cuta-
neous and subcutaneous infections show much variation in
therapeutic regimens with effective treatment mostly involving
itraconazole [40,489]. There were cases that failed to respond
to treatment with terbinaﬁne, itraconazole and amphotericin
B, but some showed signiﬁcant improvement with posaconaz-
ole [85,487,494]. Very few studies on the in vitro susceptibility
of this pathogen have been reported; it demonstrates high
MICs for most antifungal drugs (Table 2) with the exception of
posaconazole and itraconazole [487,494].
Conclusion
Although previously reported as rare agents of infections the
melanized fungi are now emerging as an important fungal
disease in humans and animals. These infections have not been
studied in clinical trials and so far the available therapeutic data
are primarily based on sporadic case reports. Furthermore,
the diagnosis depends on a high index of clinical suspicion along
with accurate mycological ﬁndings. There are no standardized
therapies for infections caused by dematiaceous fungi but
voriconazole, posaconazole, itraconazole and in some cases
amphotericin B demonstrate the most consistent in vitro
activity against this group of fungi. Oral itraconazole had been
considered the drug of choice for most situations, given the
extensive clinical experience with this agent. However, voric-
onazole may have advantages for central nervous system
infections because of its ability to achieve good cerebrospinal
ﬂuid levels, unlike itraconazole. Posaconazole is a broad-spec-
trum alternative that is well-tolerated, though backed by less
clinical experience but with excellent salvage treatment results
after failure of other antifungal agents. Amphotericin B has
been useful in some cases. As a result of the large variability in
the spectrum of dematiaceous fungi, it is important to obtain in
vitro susceptibilities of the individual patient’s fungal isolate
although it has not been ﬁrmly established that results
obtained from susceptibility testing translate into better clinical
outcomes.
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